MedPath

The Comparison of Single Catheter and Double Catheter Adrenal Vein Sampling Methods Based on the Upper Limb Approach

Not Applicable
Not yet recruiting
Conditions
Primary Aldosteronism
Registration Number
NCT06737848
Lead Sponsor
Army Medical University, China
Brief Summary

Primary Aldosteronism (PA) is a clinical syndrome characterized by the autonomous overproduction of aldosterone by the adrenal cortex's zona glomerulosa, leading to hypertension, elevated aldosterone levels, and suppressed renin activity as the primary manifestations. Studies have shown that the prevalence of PA in an unselected hypertensive population ranges from 5% to 11% , while the prevalence in patients with resistant hypertension is approximately 20% . PA is one of the most common causes of secondary hypertension , and its prevalence increases with rising blood pressure levels. Due to the adverse effects of PA on the heart, arterial walls, and kidneys, it contributes to the occurrence of cardiovascular events, with atrial fibrillation being the most common . In summary, PA is characterized by rapid onset, significant symptoms, obscurity, and severe complications, making early diagnosis and targeted treatment essential for prevention.

This study aims to explore a quasi-selected prospective randomized controlled method to compare the clinical efficacy differences between single-catheter and dual-catheter adrenal sampling via the right upper limb approach. The study seeks to clarify the effectiveness and safety of single-catheter sampling from the upper limb, providing a more efficient and cost-effective solution for the subtype diagnosis of patients with Primary Aldosteronism (PA).

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Patients aged 18-70 years with hypertension.
  • Initial screening shows a standing aldosterone/renin ratio (ARR) > 3.7, a baseline aldosterone level > 10 ng/dl, aldosterone level > 6 ng/dl after a saline load test, or aldosterone decrease of less than 30% after a captopril suppression test, consistent with a diagnosis of primary aldosteronism.
  • Voluntary participation in the trial, with signed informed consent.
Exclusion Criteria
  • Patients with an allergy to iodinated contrast agents.
  • Patients who are pregnant, breastfeeding, or planning to become pregnant.
  • Patients with severe comorbidities, such as renal failure, liver cirrhosis, metastatic tumors, or those who have had an acute stroke or acute myocardial infarction, as well as patients with a history of surgery within the past month.
  • Patients suspected of having adrenal cortical carcinoma.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Success rate of left-sided adrenal vein sampling between two groups7 month(End of Trial)

Biochemical analysis of puncture-point blood samples: A selection index (SI) ≥ 2, defined as the ratio of adrenal plasma cortisol concentration (PCC) to peripheral PCC, indicates successful unilateral aldosterone venous sampling (AVS).

Secondary Outcome Measures
NameTimeMethod
Change of material costs between two groups7 month(End of Trial)
Change of average operation time of left-side adrenal vein sampling between two groups7 month(End of Trial)

The surgical doctor will record the operation time for adrenal vein sampling from the left adrenal vein and compare change of the average operation time between the two groups at end of the study.

Change of average fluoroscopy time of adrenal vein sampling between two groups7 month(End of Trial)

Change of average fluoroscopy time of adrenal vein sampling between two groups at the end of the study.

Change of the surgical supplies cost between two groups7 month(End of Trial)

Change of the surgical supplies cost between two groups at the end of the study.

© Copyright 2025. All Rights Reserved by MedPath